Combo Therapy Clears More Hepatitis B Antigen
In an early trial, adults with chronic hepatitis B saw higher rates of surface antigen loss on a triple regimen than on standard treatment.
Updated on Nov. 6, 2026 in Diseases — General

Brii Biosciences reported phase 2 ENHANCE data showing that adding BRII-179 and elebsiran to peginterferon alfa increased hepatitis B surface antigen (HBsAg) loss compared with peginterferon alfa alone in people with chronic hepatitis B. The findings were presented ahead of The Liver Meeting 2026 and are most relevant to adults living with chronic HBV who may one day be treated with finite, add-on regimens.
Why it matters
Most current hepatitis B drugs suppress the virus but rarely clear HBsAg, so people often need long-term treatment. A regimen that produces HBsAg loss in a meaningful share of patients points toward the functional cure that researchers increasingly treat as the goal for finite therapies.
The data come from a randomized phase 2 trial in which 147 participants without cirrhosis were assigned 2:1 to triple therapy or 48 weeks of peginterferon alfa alone, with HBsAg loss at week 48 as the primary endpoint. Results are company-presented and not yet peer-reviewed, and all study sites were in China.
The players
Brii Biosciences
A biopharmaceutical company developing treatments for chronic hepatitis B, including the BRII-179 and elebsiran regimens studied in ENHANCE and ENRICH.
U.S. Food and Drug Administration
The federal agency that regulates drugs in the United States and, on October 20, 2026, approved bepirovirsen (Hibsago) for chronic hepatitis B.
The details
Nucleos(t)ide analogues suppress hepatitis B replication but seldom clear HBsAg, the viral protein whose disappearance marks functional cure. In ENHANCE Part A-1, participants received triple therapy of BRII-179, elebsiran, and peginterferon alfa, or peginterferon alfa alone, and the study tracked HBsAg levels at the end of treatment and 24 weeks later. In a separate ENHANCE Part A2 arm, 24 weeks of BRII-179 and elebsiran was followed by 24 weeks of elebsiran plus peginterferon alfa, and investigators noted that this priming allowed peginterferon alfa treatment to be cut in half.
Timeline
October 20, 2026: The U.S. Food and Drug Administration approved bepirovirsen (Hibsago) for chronic hepatitis B.
November 5, 2026: Brii Biosciences announced the ENHANCE and ENRICH findings.
November 5-9, 2026: The Liver Meeting 2026 was held in Denver, where the data were presented.
Health Landscape
The approval of bepirovirsen (Hibsago) in October 2026 signaled regulatory openness to finite hepatitis B treatments aimed at functional cure. Brii's data add an earlier-stage triple-therapy approach that remains in phase 2 and has not yet been tested beyond the study sites in China.
If you have chronic hepatitis B, these results are a reason to discuss with your doctor whether your current monitoring includes HBsAg testing and what a functional cure would mean for your long-term plan. The data are early and company-presented, so they do not change current care, but they are worth raising at your next visit.
The takeaway
Functional cure, marked by sustained HBsAg loss, is becoming the target researchers use to judge finite hepatitis B therapies. If you are living with chronic hepatitis B, ask your doctor how your HBsAg levels are being tracked and whether a clinical trial or new regimen may be relevant to you.
Further reading
For more background on chronic infections and how treatment goals are evaluated, explore the Diseases — General section.


